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A 53-year-old woman was diagnosed with gastrointestinal stromal tumor (GIST) of the stomach. Computed tomography 
(CT) revealed a huge mass (12 cm in diameter), likely to invade pancreas and spleen. In the operation field, the tumor was in 
an unresectable state. The patient was then started on imatinib therapy for 4 months. On follow-up imaging studies, the tu-
mor almost disappeared. We performed total gastrectomy and splenectomy upon which two small-sized residual tumors 
were found on microscopy. In this paper, we describe a case of clinicopathologic change in unresectable GIST after neo-
adjuvant imatinib mesylate.
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INTRODUCTION
Gastrointestinal stromal tumors (GIST) are the most 
common mesenchymal tumor of the human gastro-
intestinal tract, which arise from intestinal cells of Cajal 
[1]. Before the imatinib (Glivec, Novartis Korea, Seoul, 
Korea) era, surgery was the only therapeutic treatment for 
GIST. Even after the complete resection of GIST, however, 
most patients with advanced disease relapsed making the 
prognosis of patients with metastatic and/or recurrent 
GIST extremely poor [2]. 
Although a number of experiences have been reported 
with imatinib mesylate (IM) in patients with unresectable 
or metastatic GISTs without operation, there were few re-
ports about neoadjuvant experience in those cases. We re-
port a case of unresectable gastric GIST who underwent 
neoadjuvant therapy followed by surgical resection.
CASE REPORT
A 53-year-old female was admitted to our department Neoadjuvant in gastrointestinal stromal tumor
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Fig. 3. Histological study showing spindle cell tumor (H&E, x100). 
Fig. 4.  Immunohistochemistry finding revealing positive staining 
for CD34 (×10).
Fig. 1. Computed tomography and fluorodeoxyglucose-positron emission tomography (FDG-PET) computed tomography (CT) scans. 
Images showed a huge heterogeneous mass that is originated from stomach (A) and the tumor seemed to invade pancreas and spleen (B). A 
FDG-PET CT scan showed FDG uptake in the lesion (C).
Fig. 2. Endoscopic finding of a huge subepithelial lesion with 
central ulceration was noticed on fundus.
of general surgery because of dyspepsia and vomiting 
during the previous month. For her past history, she was 
diagnosed with diabetes and hypertension 10 years prior 
under medical treatment. There was no significant family 
history. On abdominal physical examination, there was no 
significant finding. Laboratory findings were nonspecific. 
Contrast-enhanced abdominal computed tomography 
(CT) and F-18 fluorodeoxyglucose positron emission to-
mography (FDG-PET) CT showed an approximately 12 
cm sized heterogeneous mass located from fundus to mid 
body of stomach, which seemed to invade pancreas, 
spleen and left adrenal gland (Fig. 1A-C). Endoscopic bi-
opsy performed in our institution and pathologic report 
revealed a spindle cell tumor consistent with GIST (Figs. 2, 
3). Results of immunohistochemical stain: the tumor cell 
was positive for CD34 and c-kit (CD117), weak positive for Gil Ho Kang, et al.
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Fig. 6. On the endoscopy, the mass lesion was invisible and just 
ulcerative lesion was observed.
Fig. 7. Fluorodeoxyglucose-positron 
emission tomography showed a hy-
permetabolic lesion around medial 
side of spleen.
Fig. 8. Histological study showing a residual tumor in fibrotic 
tissue (H&E, ×20).
Fig. 5. Neoadjuvant therapy with imatinib for 4 months: there was 
no evidence of mass lesion in stomach on computed tomography.
smooth muscle actin; whereas S-100 was negative (Fig. 4).
Two weeks later, we performed laparotomy, but the 
mass was huge and invaded the pancreas and retro-
peritoneum very tightly so that it couldn’t be resected. Ten 
days after the operation, the patient was started on im-
atinib therapy, a daily dose of 400 mg, maintained for 4 
months. No adverse event occured during imatinib 
treatment. A follow-up CT, 2 months after the start of im-
atinib, showed a dramatic reduction in the size of the 
tumor. And 4 months after follow-up CT, there was no evi-
dence of mass lesion in the stomach (Fig. 5); on the gastro-
duodenoscopy, the mass lesion was invisible with only an 
ulcerative lesion observed in the same location (Fig. 6). 
Although the mass lesion was not revealed clearly at the 
follow-up imaging study (Fig. 7), we planned operation to Neoadjuvant in gastrointestinal stromal tumor
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achieve curative resection of the tumor. 5 months after the 
treatment with imatinib, the patient underwent total gas-
trectomy and splenectomy. The stomach was adhered to 
the spleen, tightly, and the lesion was found between 
stomach and spleen, firm and white, having irregular 
margin. Pathologically, very few tumor cells were in the fi-
brotic tissue; residual tumor size was 0.3 × 0.2 cm and 0.2 × 
0.2 cm, respectively. The tumor consisted of spindle cells 
with a mitotic activity index of 1/50 HPF on microscopy. 
Around the residual tumor, hyalinized fibrosis, inflamed 
granulation tissue, dystrophic calcification, and necrosis 
and abscess were seen (Fig. 8). After surgery, the patient 
was discharged without any special complications. 
DISCUSSION
GIST is the most common mesenchymal tumor of the 
gastrointestinal tract. Up to two-thirds of GISTs show ma-
lignant behavior with high recurrence rates [3]. The main 
treatment of GIST is complete surgical resection. There-
fore, improving the rate of complete resection is a key chal-
lenge in the treatment of GISTs. Neoadjuvant therapy with 
tyrosine kinase inhibition has potential usefulness in pri-
mary GIST, although not yet as a standard of care [4]. 
Several retrospective studies suggested that resection of 
residual lesions could prolong progression-free survival if 
it is done while the tumors are under control with imatinib 
[5]. It is also emphasized that imatinib should be con-
tinued even after complete resection of all visible disease 
[6]. However, the role of resection of residual tumors after 
imatinib therapy has not been established, and several 
phase III clinical trials to investigate the role of surgical re-
section in this setting are ongoing or planned worldwide 
[7].
There is no disagreement on the benefit of treatment 
with imatinib for malignant GISTs, but the clinical out-
come of neoadjuvant treatment with imatinib is not well 
established [8]. In our case, we could perform complete re-
section of the GIST by down-sizing of the tumor after treat-
ment with imatinib. The duration of neoadjuvant therapy 
with imatinib may vary according to response to the treat-
ment, but surgery may be performed after sufficient 
shrinkage of tumors is observed; typically after 4 to 6 
months and within 12 months of imatinib treatment [6]. 
The standard initial dose of imatinib is 400 mg per day in 
patients with unresectable or metastatic GISTs. In a 
randomized phase III trial that compared 400 mg daily 
with 800 mg daily, the 800 mg daily was a more toxic but 
not more effective dose [9].
The goal of surgery is complete resection of tumor, pos-
sibly avoiding the occurrence of tumor rupture and ach-
ieving negative margins [7]. In our case, there was no tu-
mor rupture during the operative procedure and patho-
logically negative margins were obtained.
Radiographic tumor response to preoperative imatinib 
correlated significantly with complete resection, with 91% 
of patients with partial responses achieving complete re-
section, versus 4% of patients with progressive disease 
[10].
Radiographic and metabolic complete response based 
upon FDG-PET are not always concordant with a patho-
logic complete response; therefore, it should be born in 
mind that the pathological evaluation on the surgically re-
sected materials obtained from patients treated with IM 
might be indispensable for the elucidation of the ther-
apeutic effect of IM on GIST [10]. In our case, follow-up 
PET showed a hypermetabolic lesion around medial side 
of the spleen; residual tumor was observed in that site on 
microscopy, but follow-up CT showed no evidence of 
mass lesion in the stomach. In the surgical findings, the le-
sion had extensive areas of fibrotic changes and there were 
severe adhesions between the lesion and spleen, so it was 
suspected to be invasion, thus we performed total gas-
trectomy and splenectomy.
This case report has some limitations. First, the patient’s 
follow-up period is short and will not be an accurate prog-
nostic assessment. Second, the first surgery could have 
been avoided. In the case of lesion suspected to be in an in-
operable state, neoadjuvant chemotherapy should take 
precedence over surgical procedure.
In summary, we report a case of GIST in an unresectable 
state, initially, who underwent complete surgical resection 
following imatinib treatment. In cases of advanced GISTs, 
neoadjuvant treatment with imatinib may provide an op-
portunity for surgeons to perform a complete resection.Gil Ho Kang, et al.
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